Biogen (BIIB)
(Delayed Data from NSDQ)
$217.81 USD
-0.25 (-0.11%)
Updated May 24, 2024 04:00 PM ET
After-Market: $217.88 +0.07 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Price, Consensus and EPS Surprise
BIIB 217.81 -0.25(-0.11%)
Will BIIB be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BIIB
Why Is Biogen (BIIB) Up 7.7% Since Last Earnings Report?
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
Other News for BIIB
Biogen’s Strategic Diversification and Financial Strategy Garner Outperform Rating
Strategic Acquisitions and Clinical Catalysts Bolster Biogen’s Buy Rating
Biotech Alert: Searches spiking for these stocks today
Biogen (BIIB) Gets a Buy from Oppenheimer
Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK), Biogen (BIIB) and Clene (CLNN)